News

We are excited to be part of this week's Venous Edge issue with our blueflow Venous Stent.

The article includes a case performed by Dr. Michael Lichtenberg - CFV recanalization with a dedicated braided nitinol venous stent. #blueflow

Take a look at...

Read more

blueflow has confirmed impressively its superiority over laser-cut stents when used below the inguinal ligament. 

Click here to see the LinkedIn Post and here to get more information about the publication. 

Read more

The latest publication: Braided nitinol stent for chronic iliofemoral venous disease by Michael Lichtenberg, Stefan Stahlhoff, Ahmet Özkapi and Rick de Graaf. 

 

Click here to see the LinkedIn Post and the publication. 

Read more

We are proud to share that we will be part of this years CLI Congress.

 

Click here to see the LinkedIn Post. 

Read more

Another successful BYCROSS case. 69 year-old patient with a history of lifestyle-limiting claudication of both legs for more than 6 months now. Pre-interventional imaging revealed short-segment bilateral SFA lesions.

The intervention from the 16th...

Read more

plus medica Austria is pleased to announce the first BYCROSS use in Austria with Professor Oliver Schlager at the AKH Wien within our limited market release. Many thanks to Professor Schlager and the team Division of Angiology.

77 year-old patient...

Read more

Another successful BYCROSS case done by Prof. Ralf Kolvenbach and his team at Augusta-Krankenhaus in Düsseldorf.

Thanks a lot to the team Augusta-Krankenhaus.

Click here to see the LinkedIn Post.

Read more

First successful BYCROSS cases in Germany at the University Hospital in Heidelberg after announcing our limited market release.

A big thank you to Prof. C. Erbel, Dr. M. Dufner, Dr. F. Linden and their team!

Click here to see the LinkedIn Post.

Read more

We are excited to inform you that our BYCROSS rotational thrombectomy and atherectomy catheter received CE approval.

Our special thanks to Prof. Ralf Kolvenbach and Dr. Jörg Teßarek for conducting the study, ongoing trust in the BYCROSS technology...

Read more